The Role of COX-2 in Intestinal Inflammation and Colorectal Cancer

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2009 Dec 1

PMID 19946329

Citations 369

Authors

D Wang

R N DuBois

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC. As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is associated with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC. The epidemiological studies, clinical trials and animal experiments indicate that NSAIDs are among the most promising chemopreventive agents for this disease. NSAIDs exert their anti-inflammatory and antitumor effects primarily by reducing prostaglandin production by inhibition of COX-2 activity. In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease. These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment.

Citing Articles

Repurposing of Indomethacin and Naproxen as anticancer agents: progress from 2017 to present.

Kassab A, Gedawy E RSC Adv. 2024; 14(54):40031-40057.

PMID: 39717807 PMC: 11664213. DOI: 10.1039/d4ra07581a.

A sulfonimide derivative of bezafibrate as a dual inhibitor of cyclooxygenase-2 and PPARα.

Ammazzalorso A, Tacconelli S, Contursi A, Hofling U, Cerchia C, Di Berardino S Front Pharmacol. 2024; 15:1488722.

PMID: 39660001 PMC: 11628281. DOI: 10.3389/fphar.2024.1488722.

Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions.

Zhang H, Zhang X, Ma X, Wang X Pharmacol Rep. 2024; 77(1):72-86.

PMID: 39617815 DOI: 10.1007/s43440-024-00684-4.

Gut microbial and metabolomics profiles reveal the potential mechanism of fecal microbiota transplantation in modulating the progression of colitis-associated colorectal cancer in mice.

Song Q, Gao Y, Liu K, Tang Y, Man Y, Wu H J Transl Med. 2024; 22(1):1028.

PMID: 39548468 PMC: 11566892. DOI: 10.1186/s12967-024-05786-4.

A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells.

Qin X, Wang X, Yang C, Wang F, Fang T, Gu D Mol Divers. 2024; .

PMID: 39480610 DOI: 10.1007/s11030-024-11000-w.

References

Kawamori T, Uchiya N, Sugimura T, Wakabayashi K . Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis. 2003; 24(5):985-90. DOI: 10.1093/carcin/bgg033. View

Vane J . Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231(25):232-5. DOI: 10.1038/newbio231232a0. View

Panigrahy D, Huang S, Kieran M, Kaipainen A . PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther. 2005; 4(7):687-93. DOI: 10.4161/cbt.4.7.2014. View

Patsos H, Hicks D, Dobson R, Greenhough A, Woodman N, Lane J . The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut. 2005; 54(12):1741-50. PMC: 1774787. DOI: 10.1136/gut.2005.073403. View

Gupta R, DuBois R . Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2002; 1(1):11-21. DOI: 10.1038/35094017. View

Zhang J, Chen C . Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem. 2008; 283(33):22601-11. PMC: 2504873. DOI: 10.1074/jbc.M800524200. View

Roberts R, Min L, Washington M, Olsen S, Settle S, Coffey R . Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2002; 99(3):1521-6. PMC: 122223. DOI: 10.1073/pnas.032678499. View

Macdermott R . Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am. 1994; 78(6):1207-31. DOI: 10.1016/s0025-7125(16)30096-7. View

Kelloff G, Fay J, Steele V, Lubet R, Boone C, Crowell J . Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1996; 5(8):657-66. View

10.

Singer I, Kawka D, Schloemann S, Tessner T, Riehl T, Stenson W . Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 1998; 115(2):297-306. DOI: 10.1016/s0016-5085(98)70196-9. View

11.

Ogino S, Kirkner G, Nosho K, Irahara N, Kure S, Shima K . Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008; 14(24):8221-7. PMC: 2679582. DOI: 10.1158/1078-0432.CCR-08-1841. View

12.

Vane J, Bakhle Y, Botting R . Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38:97-120. DOI: 10.1146/annurev.pharmtox.38.1.97. View

13.

Rodriguez D, Tapia J, Fernandez J, Torres V, Munoz N, Galleguillos D . Caveolin-1-mediated suppression of cyclooxygenase-2 via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol Biol Cell. 2009; 20(8):2297-310. PMC: 2669036. DOI: 10.1091/mbc.e08-09-0939. View

14.

Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W . Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A. 2006; 103(50):19069-74. PMC: 1748178. DOI: 10.1073/pnas.0607948103. View

15.

Eberhart C, Coffey R, Radhika A, Giardiello F, Ferrenbach S, DuBois R . Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107(4):1183-8. DOI: 10.1016/0016-5085(94)90246-1. View

16.

Liu C, Chang S, Narko K, Trifan O, Wu M, Smith E . Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001; 276(21):18563-9. DOI: 10.1074/jbc.M010787200. View

17.

Eaden J . Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18 Suppl 2:15-21. DOI: 10.1046/j.1365-2036.18.s2.3.x. View

18.

Jiang G, Nieves A, Im W, Old D, Dinh D, Wheeler L . The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther. 2006; 320(1):22-8. DOI: 10.1124/jpet.106.111146. View

19.

Buchanan F, Holla V, Katkuri S, Matta P, DuBois R . Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007; 67(19):9380-8. DOI: 10.1158/0008-5472.CAN-07-0710. View

20.

Miedany Y, Youssef S, Ahmed I, El Gaafary M . The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006; 101(2):311-7. DOI: 10.1111/j.1572-0241.2006.00384.x. View